xortx therapeutics inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. it has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. the company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. in addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. the company has a strategic alliance with teijin pharma limited to develop tmx-049, a xanthine oxidoreductase; and a partnership with the icahn school of medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with covid-19. xortx therapeutics inc. is headquartered in calgary, canada.
Company profile
Ticker
XRTX
Exchange
Website
CEO
Allen Davidoff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
XRTX stock data
Latest filings (excl ownership)
NT 20-F
Notice of late annual filing (foreign)
1 May 24
6-K
Current report (foreign)
30 Apr 24
6-K
XORTX Announces Publication of Key Research in ADPKD
22 Apr 24
6-K
XORTX Welcomes New Member to the Board of Directors
8 Apr 24
6-K
XORTX Announces Participation in Spring 2024 Investor Conferences
8 Apr 24
6-K
XORTX Announces New Clinical Advisory Board Member
27 Mar 24
6-K
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
19 Mar 24
6-K
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
3 Jan 24
6-K
XORTX Welcomes New Member to the Board of Directors
2 Jan 24
6-K
XORTX Announces US ATM Offering
30 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
2.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 26.63 mm |
Total shares | 41.12 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Citadel Advisors | 28.11 k | $18.27 mm |
Advisor | 10.38 k | $6.74 mm |
Clearstead Advisors | 2.50 k | $1.62 mm |
RY Royal Bank Of Canada | 121.00 | $0.00 |
BAC Bank Of America | 2.00 | $1.00 k |
Proequities | 0.00 | $0.00 |
News
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
18 Mar 24
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
6 Mar 24
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
5 Mar 24
XORTX Finalized $2.7M Prospectus Supplement and Concurrent Private Placement for the Offering of Units
4 Mar 24